Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pruritus 2Piebaldism 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Mastocytosis, Systemic 2Mastocytosis 2Gastrointestinal Stromal Tumors 2Blushing 2Recurrence 1Multiple Myeloma 1Metastatic Castrate Resistant Prostate Cancer 1Melanoma 1Gastro-Intestinal Stromal Tumour 1Colorectal Neoplasms 1

Interventions

Gemcitabine 74Fluorouracil 31Oxaliplatin 21Leucovorin 21130-nm albumin-bound paclitaxel 17Capecitabine 14Irinotecan 12Albumin-Bound Paclitaxel 10irinotecan sucrosofate 8Radiotherapy 6Taxes 5Erlotinib Hydrochloride 5folfirinox 4rubitecan 3Surgical Procedures, Operative 3Specimen Handling 3Pancreaticojejunostomy 3Neoadjuvant Therapy 3Drug Therapy 3Cisplatin 3Chemotherapy, Adjuvant 3ruxolitinib 2masitinib 2dehydroftorafur 2Saline Solution 2S 1 (combination) 2Paclitaxel 2GV1001 peptide 2Fentanyl 2Bevacizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Pancreatic Neoplasms × masitinib × Clear all
NCT03766295 2020-12-08

Masitinib Plus Gemcitabine in Pancreatic Cancer

AB Science

Phase 3 Completed
377 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00789633 2018-12-17

Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer

AB Science

Phase 3 Completed
353 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡